Search

Your search keyword '"Huang, Huiqiang"' showing total 376 results
Start Over Author "Huang, Huiqiang" Publication Year Range Last 10 years
376 results on '"Huang, Huiqiang"'

1. CDK4/6 inhibition augments anti-tumor efficacy of XPO1 inhibitor selinexor in natural killer/T-cell lymphoma

Author

Wang, Yali, Chen, Jianfeng, Gao, Yan, Chai, Kelila Xin Ye, Hong, Jing Han, Wang, Peili, Chen, Jinghong, Yu, Zhaoliang, Liu, Lizhen, Huang, Cheng, Taib, Nur Ayuni Muhammad, Lim, Kerry May Huifen, Guan, Peiyong, Chan, Jason Yongsheng, Huang, Dachuan, Teh, Bin Tean, Li, Wenyu, Lim, Soon Thye, Yu, Qiang, Ong, Choon Kiat, Huang, Huiqiang, and Tan, Jing

Published
2024
Full Text
View/download PDF

3. Artificial intelligence for diagnosis and prognosis prediction of natural killer/T cell lymphoma using magnetic resonance imaging

Author

Zhang, YuChen, Deng, YiShu, Zou, QiHua, Jing, BingZhong, Cai, PeiQiang, Tian, XiaoPeng, Yang, Yu, Li, BingZong, Liu, Fang, Li, ZhiHua, Liu, ZaiYi, Feng, ShiTing, Peng, TingSheng, Dong, YuJun, Wang, XinYan, Ruan, GuangYing, He, Yun, Cui, ChunYan, Li, Jiao, Luo, Xiao, Huang, HuiQiang, Chen, HaoHua, Li, SongQi, Sun, Ying, Xie, ChuanMiao, Wang, Liang, Li, ChaoFeng, and Cai, QingQing

Published
2024
Full Text
View/download PDF

4. China Anti-Cancer Association (CACA) guidelines for holistic integrative management of lymphoma (version 2022)

Author

Zhang, Qingyuan, Feng, Jifeng, Wang, Huaqing, Huang, Huiqiang, Zhang, Huilai, Li, Xiaoqiu, Gao, Yuhuan, Song, Yongping, Li, Zhiming, Bai, Ou, Cao, Junning, Zhou, Hui, Gu, Kangsheng, Zhao, Shu, Zhao, Wenhui, Qin, Yan, Li, Yajun, Ma, Guangyu, Wen, Shujuan, Wang, Yu, Zhao, Peiqi, Guo, Wei, Lv, Fangfang, Tian, Yuyang, Chen, Xinrui, Xie, Zucheng, and Shi, Yuankai

Published
2023
Full Text
View/download PDF

6. Aberrant JAK-STAT signaling-mediated chromatin remodeling impairs the sensitivity of NK/T-cell lymphoma to chidamide

Author

Chen, Jinghong, Zuo, Zhixiang, Gao, Yan, Yao, Xiaosai, Guan, Peiyong, Wang, Yali, Li, Zhimei, Liu, Zhilong, Hong, Jing Han, Deng, Peng, Chan, Jason Yongsheng, Cheah, Daryl Ming Zhe, Lim, Jingquan, Chai, Kelila Xin Ye, Chia, Burton Kuan Hui, Pang, Jane Wan Lu, Koh, Joanna, Huang, Dachuan, He, Haixia, Sun, Yichen, Liu, Lizhen, Liu, Shini, Huang, Yuhua, Wang, Xiaoxiao, You, Hua, Saraf, Sahil Ajit, Grigoropoulos, Nicholas Francis, Li, Xiaoqiu, Bei, Jinxin, Kang, Tiebang, Lim, Soon Thye, Teh, Bin Tean, Huang, Huiqiang, Ong, Choon Kiat, and Tan, Jing

Published
2023
Full Text
View/download PDF

8. Treating relapsed/refractory mature T- and NK-cell neoplasms with tislelizumab: a multicenter open-label phase 2 study

Author

Bachy, Emmanuel, Savage, Kerry J., Huang, Huiqiang, Kwong, Yok-Lam, Gritti, Giuseppe, Zhang, Qingyuan, Liberati, Anna Marina, Cao, Junning, Yang, Haiyan, Hao, Siguo, Hu, Jianda, Zhou, Keshu, Petrini, Mario, Russo, Filomena, Zhang, Huilai, Sang, Wei, Ji, Jie, Ferreri, Andrés José María, Damaj, Gandhi Laurent, Liu, Hui, Zhang, Wei, Ke, Xiaoyan, Ghiggi, Chiara, Huang, Sha, Li, Xiaotong, Yao, Hui, Paik, Jason, Novotny, William, Zhou, Wenxiao, Zhu, Hongjie, and Zinzani, Pier Luigi

Published
2023
Full Text
View/download PDF

10. Frontline treatment with zanubrutinib plus rituximab (ZR) followed by short course R-DHAOx in patients with mantle cell lymphoma (MCL): Results of the phase II CHESS clinical trial.

Author

Cai, Qingqing, primary, Xia, Yi, additional, Huang, Huiqiang, additional, Li, Zhiming, additional, Huang, He, additional, Li, Guowei, additional, Zhang, Yuchen, additional, Cao, Yi, additional, Gao, Yan, additional, Liu, PanPan, additional, Fang, Xiaojie, additional, Mie, Man, additional, Tian, Xiaopeng, additional, Sun, Xiuhua, additional, and Pan, Xueyi, additional

Published
2024
Full Text
View/download PDF

19. Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study

Author

Huang, Huiqiang, Zhu, Jun, Yao, Ming, Kim, Tae Min, Yoon, Dok Hyun, Cho, Seok-Goo, Eom, Hyeon Seok, Lim, Soon Thye, Yeh, Su-peng, Song, Yuqin, Kwong, Yok Lam, Kim, Jin Seok, Jin, Jie, Shi, Yuankai, Kim, HyeJin, Qing, Min, Zhou, Tianyuan, Gao, Grace, Dong, Zongqi, Qi, Ming, and Kim, Won Seog

Published
2021
Full Text
View/download PDF

21. A Nomogram Model Based on the Inflammation-Immunity-Nutrition Score (IINS) and Classic Clinical Indicators for Predicting Prognosis in Extranodal Natural Killer/T-Cell Lymphoma.

Author

He, Yanxia, Luo, Zhumei, Chen, Haoqing, Ping, Liqing, Huang, Cheng, Gao, Yan, and Huang, Huiqiang

Subjects
NOMOGRAPHY (Mathematics), RECEIVER operating characteristic curves, DECISION making, OVERALL survival, PROGNOSIS
Abstract

Background: Systemic inflammation, immunity, and nutritional status are closely related to patients' outcomes in several kinds of cancers. This study aimed to establish a new nomogram based on inflammation-immunity-nutrition score (IINS) to predict the prognosis of extranodal natural killer/T-cell lymphoma (ENKTL) patients. Methods: The clinical data of 435 patients with ENTKL were retrospectively reviewed and randomly assigned to training cohort (n=305) and validation cohort (n=131) at a ratio of 7:3. Cox regression analysis was employed to identify independent prognostic factors and develop a nomogram in the training cohort. Harrell's concordance index (C-index), calibration curve, receiver operating characteristic (ROC) curve, and decision curve analysis (DCA) curve were employed to assess the performance of the nomogram and compare it with traditional prognostic systems (PINK, IPI, KPI). Internal validation was performed using 1000 bootstrap resamples in the validation cohort. Kaplan-Meier survival analyses were conducted to compare the overall survival (OS) of patients in different risk groups. Results: In the training cohort, in addition to several classic parameters, IINS was identified as an independent prognostic factor significantly associated with the OS of patients. The nomogram established based on the independent prognostic indicators showed superior survival prediction efficacy, with C-index of 0.733 in the training cohort and 0.759 in the validation cohort compared to the PINK (0.636 and 0.737), IPI (0.81 and 0.707), and KPI (0.693 and 0.639) systems. Furthermore, compared with PINK, IPI, and IPI systems, the nomogram showed relatively superior calibration curves and more powerful prognostic discrimination ability in predicting the OS of patients. DCA curves revealed some advantages in terms of clinical applicability of the nomogram compared to the PINK, IPI, and IPI systems. Conclusion: Compared with traditional prognostic systems, the nomogram showed promising prospects for risk stratification in ENKTL patient prognosis, providing new insights into the personalized treatment. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

22. P1172: ARTIFICIAL INTELLIGENCE FOR PROGNOSIS PREDICTION OF NATURAL KILLER/T-CELL LYMPHOMA BASED ON MAGNETIC RESONANCE IMAGING

Author

Cai, Qingqing, primary, LI, Chaofeng, additional, Wang, Liang, additional, Xie, Chuanmiao, additional, Zhang, Yuchen, additional, Deng, Yishu, additional, Zou, Qihua, additional, Jing, Bingzhong, additional, Cai, Peiqiang, additional, Tian, Xiaopeng, additional, Cao, Yi, additional, Yang, Yu, additional, LI, Bingzong, additional, Liu, Fang, additional, LI, Zhihua, additional, Liu, Zaiyi, additional, Feng, Shiting, additional, Peng, Tingsheng, additional, Dong, Yujun, additional, Wang, Xinyan, additional, Ruan, Guangying, additional, He, Yun, additional, Huang, Huiqiang, additional, and Liang, Yang, additional

Published
2023
Full Text
View/download PDF

26. P1136: FIRST INTERIM ANALYSIS OF A PHASE 1 STUDY OF ZANUBRUTINIB PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA

Author

Zhang, Huilai, primary, Cheng, Ying, additional, Yang, Hai-Yan, additional, Zhang, Liling, additional, Zou, Liqun, additional, Guo, Ye, additional, Cao, Junning, additional, Huang, Huiqiang, additional, Wang, Zhao, additional, Huang, Sha, additional, Liang, Zhiyu, additional, Lyu, Jiaoyan, additional, Fang, Yiqian, additional, Cohen, Aileen, additional, and Zhou, Keshu, additional

Published
2023
Full Text
View/download PDF

27. PB2307: PHARMACOKINETICS, EFFICACY AND SAFETY OF SUBCUTANEOUS VERSUS INTRAVENOUS RITUXIMAB COMBINED WITH CHOP IN CHINESE PATIENTS WITH UNTREATED CD20-POSITIVE DIFFUSE LARGE B CELL LYMPHOMA: A RANDOMIZED TRIAL

Author

Gao, Yan, primary, Zhang, Liling, additional, Gao, Sujun, additional, Yang, Yu, additional, Zhang, Qing-Yuan, additional, Zhang, Huilai, additional, He, Pengcheng, additional, LI, Fei, additional, Jing, Hongmei, additional, Grange, Susan, additional, Bu, Lilian, additional, Wang, Qianming, additional, Wang, Yanjie, additional, and Huang, Huiqiang, additional

Published
2023
Full Text
View/download PDF

31. Sugemalimab Monotherapy for Patients With Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (GEMSTONE-201): Results From a Single-Arm, Multicenter, Phase II Study

Author

Huang, Huiqiang, primary, Tao, Rong, additional, Hao, Siguo, additional, Yang, Yu, additional, Cen, Hong, additional, Zhou, Hui, additional, Guo, Ye, additional, Zou, Liqun, additional, Cao, Junning, additional, Huang, Yunhong, additional, Jin, Jie, additional, Zhang, Liling, additional, Yang, Haiyan, additional, Xing, Xiaojing, additional, Zhang, Huilai, additional, Liu, Yanyan, additional, Ding, Kaiyang, additional, Qi, Qinzhou, additional, Zhu, Xiaoli, additional, Zhu, Dan, additional, Wang, Siyuan, additional, Fang, Teng, additional, Dai, Hangjun, additional, Shi, Qingmei, additional, and Yang, Jason, additional

Published
2023
Full Text
View/download PDF

32. Treatment patterns and clinical outcomes of mantle cell lymphoma: A retrospective cohort study by CHOICE

Author

Zeng, Dongfeng, primary, Fang, Yu, additional, Fei, Yue, additional, Liang, Rong, additional, Ye, Haige, additional, Liang, Yun, additional, Sun, Xiuhua, additional, Wang, Michael, additional, Huang, Huiqiang, additional, Qiu, Lugui, additional, Che, Yuxuan, additional, Liu, Panpan, additional, Wang, Yi, additional, Pan, Tao, additional, Lv, Yao, additional, Deng, Jintai, additional, Yi, Shuhua, additional, He, Yizi, additional, Xiao, Ling, additional, Lv, Huijuan, additional, Feng, Jiangfang, additional, Zhang, Huilai, additional, Zhou, Hui, additional, Zou, Dehui, additional, and Cai, Qingqing, additional

Published
2023
Full Text
View/download PDF

33. Recurrent ECSIT mutation encoding V140A triggers hyperinflammation and promotes hemophagocytic syndrome in extranodal NK/T cell lymphoma

Author

Wen, Haijun, Ma, Huajuan, Cai, Qichun, Lin, Suxia, Lei, Xinxing, He, Bin, Wu, Sijin, Wang, Zifeng, Gao, Yan, Liu, Wensheng, Liu, Weiping, Tao, Qian, Long, Zijie, Yan, Min, Li, Dali, Kelley, Keith W., Yang, Yongliang, Huang, Huiqiang, and Liu, Quentin

Subjects
Gene mutations -- Physiological aspects -- Research, Non-Hodgkin's lymphomas -- Genetic aspects -- Development and progression -- Research, Biological sciences, Health
Abstract

Hemophagocytic syndrome (HPS) is a fatal hyperinflammatory disease with a poorly understood mechanism that occurs most frequently in extranodal natural killer/T cell lymphoma (ENKTL). Through exome sequencing of ENKTL tumor-normal samples, we have identified a hotspot mutation (c.419T [greater than] C) in the evolutionarily conserved signaling intermediate in Toll pathway (ECSIT) gene, encoding a V140A variant of ECSIT. ECSIT-V140A activated NF-[kappa]B more potently than the wild-type protein owing to its increased affinity for the S100A8 and S100A9 heterodimer, which promotes NADPH oxidase activity. ECSIT-T419C knock-in mice showed higher peritoneal NADPH oxidase activity than mice with wild-type ECSIT in response to LPS. ECSIT-T419C-transfected ENKTL cell lines produced tumor necrosis factor (TNF)-[alpha] and interferon (IFN)-[gamma], which induced macrophage activation and massive cytokine secretion in cell culture and mouse xenografts. In individuals with ENKTL, ECSIT-V140A was associated with activation of NF-[kappa]B, higher HPS incidence, and poor prognosis. The immunosuppressive drug thalidomide prevented NF-[kappa]B from binding to the promoters of its target genes (including TNF and IFNG), and combination treatment with thalidomide and dexamethasone extended survival of mice engrafted with ECSIT-T419C-transfected ENKTL cells. We added thalidomide to the conventional dexamethasone-containing therapy regimen for two patients with HPS who expressed ECSIT-V140A, and we observed reversal of their HPS and disease-free survival for longer than 3 years. These findings provide mechanistic insights and a potential therapeutic strategy for ENKTL-associated HPS., Author(s): Haijun Wen [1, 2, 3]; Huajuan Ma [1, 4]; Qichun Cai [1, 5, 6]; Suxia Lin [1, 7]; Xinxing Lei [1]; Bin He [1]; Sijin Wu [8]; Zifeng Wang [...]

Published
2018
Full Text
View/download PDF

36. First‐line immunotherapy with anti‐PD‐1 antibody for extranodal NK/T‐cell lymphoma: A retrospective study.

Author

Wang, Xiaoxiao, Wen, Lei, Liao, Jing, Feng, Yanfen, Li, Yuhong, Zhou, Zhaoming, Zhou, Cheng, and Huang, Huiqiang

Subjects
IMMUNOGLOBULINS, IMMUNOTHERAPY, LYMPHOMAS, PROGNOSIS, RETROSPECTIVE studies
Abstract

Summary: Anti‐PD‐1 antibody has shown certain effects in patients with newly diagnosed extranodal NK/T‐cell lymphoma (ENKTL). Here, we evaluated the clinical efficacy and safety of first‐line anti‐PD‐1 antibody for the treatment of patients with ENKTL and explored biomarkers for treatment response. The clinical data of 107 patients with newly diagnosed ENKTL were retrospectively analysed. Patients received either first‐line anti‐PD‐1 antibody induction treatment or anti‐PD‐1 antibody combined with asparaginase‐based chemotherapy (immunochemotherapy). We found that immunochemotherapy was an independent prognostic factor for longer PFS (p < 0.001). The overall response rate and complete remission rate of immunochemotherapy group was higher than immunotherapy induction group (86.11% vs. 62.86% and 72.22% vs. 52.29%, respectively, p = 0.013). We also observed pretreatment CD4/CD8 ratio >0.83 was significant associated with better response and longer PFS in ENKTL patients received first‐line anti‐PD1‐antibody. Plasma copy number of EBV decreased more significantly in patients with CD4/CD8 ratio >0.83 after treatment. PD‐L1 expression was associated with better response and PFS, while elevated plasma IL‐6, IL‐10 and IFN‐γ were associated with poor prognosis. Anti‐PD‐1 antibody treatment showed promising results in newly diagnosed ENKTL patients. The assessment of pretreatment CD4/CD8 ratio in ENKTL seems feasible for identifying responders to anti‐PD‐1 antibody treatment. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

37. Preclinical characterization of WB737, a potent and selective STAT3 inhibitor, in natural killer/T‐cell lymphoma.

Author

Wang, Yali, Zhou, Wenbo, Chen, Jianfeng, Chen, Jinghong, Deng, Peng, Chen, Huang, Sun, Yichen, Yu, Zhaoliang, Pang, Diwen, Liu, Lizhen, Wang, Peili, Hong, Jing Han, Teh, Bin Tean, Huang, Huiqiang, Li, Wenyu, Yi, Zhengfang, Lim, Soon Thye, Chen, Yihua, Ong, Choon Kiat, and Liu, Mingyao

Subjects
T-cell lymphoma, SMALL molecules, PHOSPHORYLATION, HOMOLOGY (Biochemistry), TRANSCRIPTION factors
Abstract

Natural killer/T‐cell lymphoma (NKTL) is an uncommon malignancy with poor prognosis and limited therapeutic options. Activating mutations of signal transducer and activator of transcription 3 (STAT3) are frequently found in patients with NKTL, suggesting that targeted inhibition of STAT3 is a potential therapeutic option for this disease. Here, we have developed a small molecule drug WB737 as a novel and potent STAT3 inhibitor that directly binds to the STAT3‐Src homology 2 domain with high affinity. In addition, the binding affinity of WB737 to STAT3 is 250‐fold higher than STAT1 and STAT2. Interestingly, WB737 is more selective for NKTL with STAT3‐activating mutations in terms of growth inhibition and apoptotic induction when compared with Stattic. Mechanistically, WB737 inhibits both canonical and noncanonical STAT3 signaling via suppression of STAT3 phosphorylation at Tyr705 and Ser727, respectively, thereby inhibiting the expression of c‐Myc and mitochondria‐related genes. Moreover, WB737 inhibited STAT3 more potently than Stattic, resulting in a significant antitumor effect with undetectable toxicity, followed by almost complete tumor regression in an NKTL xenograft model harboring a STAT3‐activating mutation. Taken together, these findings provide preclinical proof‐of‐concept for WB737 as a novel therapeutic strategy for the treatment of NKTL patients with STAT3‐activating mutations. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

40. Bendamustine in the treatment of patients with indolent non‐Hodgkin lymphoma refractory or relapse to rituximab treatment: An open‐label, single‐agent, multicenter study in China

Author

Gao, Yan, primary, Liu, Yizhen, additional, Wang, Yafei, additional, Zhang, Qingyuan, additional, Wu, Depei, additional, Ye, Xu, additional, Wu, Jianqiu, additional, Xu, Wei, additional, Zhou, Jianfeng, additional, Yang, Yu, additional, Cen, Hong, additional, Zhang, Feng, additional, Xiang, Ying, additional, Tang, Xiaoqiong, additional, Ding, Kaiyang, additional, Lin, JinYing, additional, Ma, Lei, additional, Wang, Shunqing, additional, Yu, Hao, additional, Zhao, Yang, additional, Song, Bin, additional, Lv, Fangfang, additional, and Huang, Huiqiang, additional

Published
2022
Full Text
View/download PDF

41. The dual role of CD70 in B‐cell lymphomagenesis

Author

Nie, Man, primary, Ren, Weicheng, additional, Ye, Xiaofei, additional, Berglund, Mattias, additional, Wang, Xianhuo, additional, Fjordén, Karin, additional, Du, Likun, additional, Giannoula, Yvonne, additional, Lei, Dexin, additional, Su, Wenjia, additional, Li, Wei, additional, Liu, Dongbing, additional, Linderoth, Johan, additional, Jiang, Chengyi, additional, Bao, Huijing, additional, Jiang, Wenqi, additional, Huang, Huiqiang, additional, Hou, Yong, additional, Zhu, Shida, additional, Enblad, Gunilla, additional, Jerkeman, Mats, additional, Wu, Kui, additional, Zhang, Huilai, additional, Amini, Rose‐Marie, additional, Li, Zhi‐Ming, additional, and Pan‐Hammarström, Qiang, additional

Published
2022
Full Text
View/download PDF

44. Sintilimab Plus P-Gemox (Pegaspargase, Gemcitabine and Oxaliplatin) Regimen for Newly-Diagnosed Advanced, Extranodal Natural Killer/T Cell Lymphoma, Nasal Type: A Multicenter, Phase 2 Cohort of the Open-Label Spirit Study

Author

Cai, Qingqing, primary, Liu, Panpan, additional, Xia, Yi, additional, Cai, Jun, additional, Huang, Huiqiang, additional, Li, Zhiming, additional, Zhou, Hui, additional, Li, Yajun, additional, Wang, Hanyu, additional, Huang, Ying, additional, Yan, Gao, additional, and Pan, Xueyi, additional

Published
2022
Full Text
View/download PDF

46. XPO1 Inhibitor (ATG-010) Plus GemOx Regimen for Heavily Pretreated Patients with Relapsed or Refractory (R/R) T and NK-Cell Lymphoma：Updates of the Phase Ib Touch Study

Author

Huang, Huiqiang, primary, Gao, Yan, additional, Zhang, Huilai, additional, Zhou, Keshu, additional, Wu, Jianqiu, additional, Cai, Zhen, additional, Jing, Hongmei, additional, Fan, LEI, additional, Lou, Sai, additional, Fei, Yizhou, additional, Wang, Aihua, additional, and Lynch, Kevin, additional

Published
2022
Full Text
View/download PDF

47. Preliminary Safety and Efficacy of Zanubrutinib in Combination with Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Author

Zhang, Huilai, primary, Zhou, Keshu, additional, Cheng, Ying, additional, Zhang, Liling, additional, Yang, Haiyan, additional, Zou, Liqun, additional, Cao, Junning, additional, Huang, Huiqiang, additional, Guo, Ye, additional, Wang, Zhao, additional, Huang, Sha, additional, Liang, Zhiyu, additional, Yao, Hui, additional, Guo, Haiyi, additional, Fang, Yiqian, additional, and Zhu, Hongjie, additional

Published
2022
Full Text
View/download PDF

49. A Prospective Study of Methotrexate in Combination with Ibrutinib and Temozolomide (MIT) in Newly Diagnosed Primary CNS Lymphoma

Author

Wang, Xiaoxiao, primary, Shan, Changguo, additional, Huang, He, additional, Li, Zhiming, additional, Zhou, Hui, additional, Gao, Yan, additional, Yu, Shanshan, additional, Hong, Xiaoyu, additional, Lai, Mingyao, additional, Yang, Chao, additional, Shao, Yang, additional, Cai, Linbo, additional, and Huang, Huiqiang, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results